来自官方财务报表的收入、利润与现金流历史。
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
| 利润表 | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $90M | $0M | $1M | $1M | $2M | $19M | $0M | $0M | $4M | $5M | $5M | $6M | — |
| 毛利 | — | ($172M) | $1M | $0M | $2M | $19M | ($2M) | ($1M) | $4M | $5M | $5M | $6M | $0M |
| 毛利率% | — | — | 100.0% | -8.8% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | 100.0% | 98.5% | — |
| 营业利润（EBIT） | ($202M) | ($210M) | ($209M) | ($242M) | ($85M) | ($66M) | ($81M) | ($80M) | ($45M) | ($28M) | ($22M) | ($11M) | ($9M) |
| 营业利润率% | -222.8% | — | -23540.2% | -27348.0% | -3640.2% | -350.3% | — | — | -1169.3% | -531.7% | -473.3% | -185.9% | — |
| 净利 | ($179M) | ($155M) | ($208M) | ($339M) | ($84M) | ($66M) | ($81M) | ($78M) | ($44M) | ($27M) | ($22M) | ($11M) | ($10M) |
| 净利润率 % | -198.3% | — | -23478.3% | -38238.2% | -3598.7% | -351.1% | — | — | -1140.6% | -523.3% | -468.8% | -185.6% | — |
| EBITDA | ($201M) | ($210M) | ($208M) | ($242M) | ($82M) | ($64M) | ($79M) | ($77M) | ($45M) | ($27M) | ($22M) | ($11M) | ($10M) |
| 每股收益（EPS） | $-0.52 | $-3.30 | $-4.42 | $-49.12 | $-24.86 | $-25.02 | $-37.89 | $-61.23 | $-53.25 | $-27.00 | $-55.40 | $-24.71 | $-10.00 |
| 已发行股数 (M) | 346M | — | 47M | 7M | 3M | 3M | 2M | 1M | 1M | 1M | 0M | 0M | 1M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 SYRE 交互式查看器。 /companies/us/SYRE
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms